The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

A woman is silhouetted against the waning rays of the late afternoon sun at Ala Moana Regional Park on Tuesday, March 12, ...

A large study of electronic health records has uncovered four common patterns of medical conditions that tend to unfold in ...

Microglia replacement therapy helps treat people with a rare genetic condition called ALSP, suggesting the approach could ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

In those nations, MAID is available to a wider universe of pained people, not just those with fewer than six months to live.

The study, which analyzed data on 1.2 million people with dementia, found improvements in five out of eight global regions ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

A promising treatment for people in the early stage of Alzheimer’s disease is the focus of a national study that will include participants in Cleveland and Columbus.

Statins, long hailed for lowering cholesterol, might offer an unexpected benefit beyond heart health—they could help slow Alzheimer’s disease. A new study suggests that these common ...

The Alzheimer’s Assoc. is preparing guidelines on blood-based biomarker tests (anticipated in 2025), cognitive assessment tools (also anticipated in 2025), and clinical implementation of staging ...